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Abstract
MicroRNAs (miRNAs) are recently discovered small non-coding RNAs and can serve as serum biomarkers for disease
diagnosis and prognoses. Lack of reliable serum miRNA endogenous references for normalization in miRNA gene expression
makes single miRNA assays inaccurate. Using TaqManH real-time PCR miRNA arrays with a global gene expression
normalization strategy, we have analyzed serum miRNA expression profiles of 20 female mice of NOD/ShiLtJ (n=8), NOR/LtJ
(n=6), and C57BL/6J (n=6) at different ages and disease conditions. We identified five miRNAs, miR-146a, miR-16, miR-195,
miR-30e and miR-744, to be stably expressed in all strains, which could serve as mouse serum miRNA endogenous
references for single assay experiments.
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Introduction
MicroRNAs (miRNAs) are a recently discovered class of 21–
25 nt single stranded non-coding RNAs, which are widely
expressed in plants, animals, and humans, and function through
translational repression of specific target mRNAs. As regulators of
gene expression, miRNAs act in a complementary fashion by
partially binding to the 39 untranslated region of target mRNAs
[1]. Repression of protein translation follows the pairing of
miRNAs to target sequences. The unique mechanism of gene
regulation make miRNAs an important regulator of a diverse set of
physiological processes [2,3], including immune cell development
[3,4,5]. miRNAs have been found to be dysregulated in multiple
disease states, most notably in cancer where expression of miRNAs
appear to be tissue-specific [6,7].
Circulating nucleic acids were first described by Mandel and
Metais in 1948, when nucleic acids were measured in human
plasma [8]. The potential use of circulating nucleic acids extended
to disease diagnosis much later, when increased levels of serum
DNA distinguished cancer patients from healthy controls [9]. In
addition, the possibility of nucleic acids as evaluators of
therapeutic effectiveness was also reported, levels of serum DNA
in cancer patients decreased when treatment was effective [10,11].
Recent studies have demonstrated that serum and plasma also
contain a large amount of stable miRNAs and have potential to
serve as biomarkers for changes in physiological and pathological
conditions, such as pregnancy, cancer, and other diseases
[12,13,14,15,16]. Circulating miRNAs show remarkable stability
and demonstrate consistent expression profiles between healthy
controls and patients [12,13,15,16]. The extraction and quanti-
fication of serum miRNAs is a challenging task, however miRNA
detection is much easier than the detection of some current protein
biomarkers. Although most studies have focused on using
circulating miRNAs as biomarkers in human, circulating miRNAs
in rodent models are able to distinguish healthy animals from
diseased animals as well [14,17,18,19].
The exciting research of circulating miRNA biomarkers has a
great potential; however, the issue currently at the forefront of
serum miRNA research is proper normalization of miRNA gene
expression with invariant housekeeping genes. Normalization of
circulating miRNA remains a significant hurdle that must be
addressed in order to facilitate biomarker discovery and fully
validate single miRNA quantitative real-time PCR (qRT-PCR)
assays. It is important to ensure that gene expression differences
are a direct result of the diseases under study and not due to other
sources of variation [20]. Uncontrolled variation can be limited
through normalization. Equal amounts of total RNA are
commonly used as the initial normalizer when conducting qRT-
PCR experiments. However, the total amount of miRNA
extracted from even the same quantities of serum or plasma from
different samples is generally not equal. Research has been done to
discover normalizers of miRNA expression in tissue samples,
which addresses the variation of RNA loading amounts between
samples. For example Peltier and Latham reported expression of
tissue miR-191 and miR-103 to be more consistent than
commonly used small RNAs and even total RNA [20]. Even
though miRNA normalizers may be present in tissue, endogenous
references specific to circulating miRNAs have not been identified.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31278In this report, we have evaluated the serum miRNA profiles of 20
individual mice from different strains using a TaqManH Array
MicroRNA real-time PCR strategy in order to identify the
miRNAs with the most stable expression in the serum of mouse.
These samples represent multiple strains of mice at different ages
as well as different conditions, including autoimmune diabetes.
Microarray analysis of 277 miRNAs, using global normalization
and subsequent data filters, identified five miRNAs as circulating
miRNA endogenous references.
Methods
Mouse
Female NOD/ShiLtJ (NOD n=8, stock# 001976), NOR/LtJ
(NOR n=6, stock# 002050), and C57BL/6J (B6 n=6, stock#
000664) (Jackson Laboratory, Bar Harbor, Maine) mice were used
for all experiments. NOD mice spontaneously develop T-cell
mediated insulin-dependent diabetes mellitus staring at 14–15
weeks old, while NOR mice only develop pancreatic insulitis
without diabetes development. All animal studies have been
approved by Institutional Animal Care and Use Committee
(IACUC).
Serum Collection
Mouse blood was collected following euthanization via heart
puncture. Blood was allowed to clot for at least 1 hour, centrifuged
for 10 minutes63,000 rpm, and supernatant (serum) was re-
moved. Centrifugation was repeated for 10 minutes62,500 rpm
and the resulting serum layer was used for RNA isolation or stored
at 280uC until further use. For NOD mice, serum was collected at
3–4 weeks, 7–8 weeks, 16–19 weeks (non-diabetic), and after
developing diabetes. For NOR and B6 mice, serum were collected
at 3–4 weeks, 7–8 weeks, and 16–19 weeks. Each time point from
each mouse strain was duplicated.
RNA Extraction and TaqManH Low-Density Array miRNA
qRT-PCR
RNA was isolated from serum samples by using a combination
of TrizolH LS (Invitrogen
TM, Carlsbad, CA) and the mirVana
TM
miRNA Isolation kit (AmbionH, Austin, TX) or the QiagenH
miRNeasyH Mini kit (Qiagen Inc.H, Germantown, MD) with some
modifications. Each sample was measured by a NanoDrop 2000
spectrophotometer (Thermo Scientific). The RNA (about 50 ng)
was reverse transcribed using the TaqManH MiRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA),
and the TaqManH MiRNA Multiplex RT Assays, Rodent pool A
(v2.0) (Applied Biosystems). 3 ml of RNA was added to each
reaction and RT-PCR was carried out on the ABI Veriti
TM
Thermal cycler (Applied Biosystems). 2.5 ml of the product from
each reverse transcription reaction was preamplified per the
manufacturer’s protocol with the Megaplex
TM PreAmp Primers
(106), Rodent pool A (v2.0), and TaqManH PreAmp Master Mix
(26) using the ABI Veriti
TM (Applied Biosystems). Following
preamplification the miRNA expression was profiled with
TaqManH Rodent MicroRNA array card A v2.0, performed on
a 7900HT Fast Real-Time PCR System (Applied Biosystems),
using the manufacturer’s recommended protocol.
Global Normalization and Statistical Analysis
Raw cycle threshold (CT) values were calculated using SDS 2.3
and RQ manager 1.2 software (Applied Biosystems) applying
automatic baselines and threshold settings. The CT values were
imported into StatMinerH 4.2 (IntegromicsH Inc., Philadelphia,
PA) for global normalization of each sample. The miRNAs that
were detected in all 20 samples were selected for the reference set
in global normalization [21]. Within each sample, the global
normalization process subtracts the mean CT value of the
reference set from the CT value of each miRNA from the same
sample. The resulting value is the DCT.E n d o g e n o u sc o n t r o l s
must be consistently expressed, thus only the miRNAs that were
expressed in all samples were considered to be candidates and
subjected to further data analysis. These DCT values were
analyzed with one-way analysis of variance (ANOVA) using
mouse strain as the predictor and the Least-significant difference
method for pair-wise comparisons using SPSS 18.0.0 (SPSS Inc.,
Chicago, IL). The miRNAs with ANOVA p-values greater than
0.3, demonstrating no significant difference between strains, were
retained as endogenous reference candidates. Endogenous
references should have a small variation among all samples.
Therefore the standard deviation (SD) across all samples was
calculated using SPSS 18.0.0. miRNAs with an SD less than 1
were selected. Finally, in order to increase the strictness of our
criteria the pair-wise |DDCT| of the candidate miRNAs were
analyzed to determine the difference in mean DCT values within
the 3 strains. Candidate miRNAs had |DDCT| values less than
0.5. Consequently genes with an ANOVA p.0.3, an SD,1, and
all pair-wise |DDCT|,0.5 were selected as endogenous reference
genes.
Results
Identification of serum miRNA endogenous references
Our data is based on 20 serum miRNA expression profiles from
B6, autoimmune-prone NOD, and NOR mouse strains, across
different ages, and with diabetes and pancreatic inflammation. A
total of 277 miRNAs were expressed between all serum samples in
the TaqManH Array MicroRNA Rodent A card, which contains
335 potential target miRNAs. The DCT values for each miRNA
were calculated using the global normalization option of the
StatMinerH software. The global normalization method is
convenient for high-throughput miRNA assays where quantities
of initial loading amounts of RNA are difficult to accurately
quantify.
Of the 277 individually expressed miRNAs, 72 displayed
consistent expression across all 20 samples (Table S1). Using
these 72 miRNAs as the global normalization reference set in
StatminerH, a heat map of all expression values (2DCT) was
generated (Figure 1). In order to be considered as potential
endogenous references, only those miRNAs that had an ANOVA
p.0.3 for the comparison of the B6, NOD, and NOR (n=20)
mouse strains were selected. This 3-group comparison provided 21
miRNAs with ANOVA p.0.3. The same criterion was applied to
the pair-wise comparison of the 21 genes which produced 10
miRNAs with least-significant difference p.0.3. These 10
miRNAs passed our initial criteria of p.0.3 and were considered
further (Table 1).
The second criterion necessary for endogenous reference
consideration were miRNAs with a SD,1. This is similar to the
criterion used to determine normalizers for miRNA expression in
various tissues [22,23]. As a result the SD values of the 10
candidate genes were calculated, and five miRNAs passed our
criteria of a p.0.3, and an SD,1. Finally, the five miRNAs also
met the criterion of all pair-wise |DDCT|,0.5 (Table 1). As
shown in Figure 2, these five serum miRNAs, miR-146a, miR-16,
miR-195, miR-30e, and miR-744 were stably expressed in mouse
regardless of strain, age, and disease condition. Furthermore, miR-
146a and miR-16 are highly expressed in serum, while miR-30e,
miR-195, and miR-744 have relatively lower expression.
Serum miRNA Endogenous References
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31278U6 is not stably expressed in mouse serum
MammU6 (U6) RNA is commonly used as a normalizer for
miRNA expression in tissues and cells [20,24]. Recently, the use of
this RNA has been extended to normalization of circulating
miRNA biomarkers [25,26,27]. As shown in Figure 3,U 6i s
expressed in all 20 samples, however, failed to meet our criteria as
an endogenous reference. Based on the global normalization, U6
displays an ANOVA p-value of 0.049 and an SD of 2.4, with at
least a 4 fold difference in the expression between NOD vs. both
B6 and NOR. Thus, U6 may not serve as a serum normalizer for
miRNAs.
Discussion
In the current study, we have defined five serum miRNAs as
endogenous references. To our knowledge this is the first study of
serum endogenous references for mouse miRNAs. Normalization
techniques for circulating miRNAs have yet to be perfected. Some
of the normalizing methods for serum or plasma miRNA reported
are adopted from tissue studies, including the use of U6, which has
stirred concern in recent studies. snoRNA and RNU6B (U6) have
been described as instable in serum and therefore cannot be used
for normalization [28]. U6 and 5S were reportedly degraded in
some serum samples [15]. As reported in our current study, our
data further confirmed that U6 is not a good candidate for an
endogenous reference for serum miRNA expression. Additionally,
miRNA miR-191 and miR-103 have been reported as internal
controls for tissue miRNA expression [20]. Serum miR-191 is
expressed in all samples, however there is a significant difference
(p=0.001) between all samples (data not shown here). Therefore,
miR-191 fails to meet our endogenous control criteria and was not
considered further as a serum miRNA internal reference.
Similarly, serum miR-103 does not have the stability as reported
in tissue samples, being only expressed in 5 of our 20 samples (data
not shown here), and does not meet our endogenous control
requirements either. Thus, tissue miRNA internal controls may
not be suitable for serum internal references.
The total miRNAs present in serum and plasma are very low,
and efficient reproducible recovery of this RNA is a challenging
task. Furthermore, the yield of RNA from small volume serum or
plasma samples has, in our hand and others, been below the limit
of accurate quantitation by OD measurement. Considerable
sample-to-sample (strain to strain in mouse) variability in both
protein and lipid content of plasma and serum samples, which
could potentially affect efficiency of RNA extraction and introduce
inhibitors of PCR reactions, will further add to the variation of
RNA extraction and efficiency of PCR reactions. In order to
adjust for those variations, C. elegans synthetic miRNAs spiked in at
the onset of the RNA isolation process has been adopted by many
researchers to provide an internal reference for normalization of
technical variations between samples [13]. However, variation of
the amount of miRNAs present in a given individual serum or
Figure 1. Global expression of serum miRNAs in different mouse strains. Serum RNA was isolated from different aged (w=weeks) mouse
strains (n=20), with each time point duplicated. The globally normalized DCT values are represented in the heat map with miRNA species ordered by
hierarchical clustering. miRNA expression was analyzed by TaqManH miRNA arrays and normalized by StatMinerH global normalization.
doi:10.1371/journal.pone.0031278.g001
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introduced by many factors, cannot be normalized by this
strategy. Invariant serum housekeeping miRNAs are urgently
needed for circulating miRNA studies [29]. Without an acceptable
standard for normalization, circulating miRNA biomarkers are
limited in claims of diagnostic discovery and evaluation because
they cannot be evaluated individually.
It is expected, theoretically, that a true endogenous reference
would be stably expressed, where expressions are not affected by
the difference of strains, age, and conditions, including diseases.
The five genes we identified here are an important discovery and
may serve as good normalizers for circulating miRNAs for several
reasons. First, 20 miRNA microarrays have been completed which
are a large number of arrays from a variety of mouse strains and
ages. Second, in addition to a low SD, a criterion successfully used
to identify tissue endogenous references [22,23], the additional
criteria, ANOVA p.0.3 and pair-wise |DDCT|,0.5, have also
been employed in our strategy in order to strengthen our
endogenous reference selection. Finally, the fact that consistent
expression of five genes in circulating miRNA expression profiles
exists from multiple mouse strains, at different ages, and with
different disease models provides strong evidence that miR-146a,
miR-16, miR-195, miR-30e, and miR-744 are useful as circulating
miRNA endogenous references. Using a selection of these
candidates, we have successfully validated some serum biomarkers
for diabetes in NOD mice as well as metastatic lung melanoma in
the mouse model by single qRT-PCR reactions following global
normalization of array data (our unpublished data).
When choosing a qRT-PCR serum endogenous reference, we
recommend careful consideration of endogenous miRNA controls
based on RNA loading amounts and miRNA expression
abundances. As shown in Figure 2, miR-146a and miR-16 are
highly expressed in serum, while miR-30e, miR-195, and miR-744
have lower expression levels. For instance, if an experiment is
working with lower abundance of miRNA, it may be worthwhile
to select those controls with lower expression in order to properly
validate the miRNA of interest. In addition, miR-146a has been
implicated in immune cell regulation, cancer, b-cell failure, and
potentially type 2 diabetes [29,30,31,32]. Therefore, more
precautions should be taken for the use of miR-146a as an
endogenous reference in certain disease models. We preformed
normalization of single qRT-PCR targets from the related mouse
disease model using miR-146a, miR-16, and miR-195. Cross
normalization of these references to each other revealed that miR-
16 and miR-195 are extremely stable endogenous references in
this particular mouse model (our unpublished data). We
recommend that suitable endogenous controls should be selected
in light of the study design and research conditions, and that the
use of 2–3 endogenous references together may additionally
reduce bias and variation [20,30,31]. Choosing more than one
reference miRNA will reduce the possibility that any endogenous
references may be regulated by specific conditions, in which these
references should not serve as endogenous references. Small fold
change differences of potential biomarkers may not be identified
with our reference genes, however we are confident that based on
the stability of the miRNAs presented here the biomarkers
Table 1. Mouse endogenous control selection process.
Candidate
miRNA ANOVA Pair-wise
p.0.3 LSD p.0.3 SD,1| DDCt|,0.5
miR-195 0.9695646 pass 0.9910273 pass
miR-30e 0.9573852 pass 0.7163731 pass
miR-146a 0.9403384 pass 0.9486185 pass
miR-16 0.8665249 pass 0.8232968 pass
miR-744 0.5773991 pass 0.7078349 pass
miR-29a 0.8524583 pass 1.0477783
miR-200c 0.7367455 pass 1.1338788
miR-let 7g 0.7352368 pass 1.2810793
miR-214 0.6059579 pass 1.2313915
miR-2965p 0.9875817 pass 2.182499
miR-133b 0.5180362 fail
miR-199a3p 0.5143139 fail
miR-5325p 0.4387915 fail
miR-146b 0.4132751 fail
miR-145 0.4100232 fail
miR-1395p 0.3748676 fail
miR-200b 0.373373 fail
miR-375 0.3580763 fail
miR-150 0.3283348 fail
miR-328 0.3274329 fail
miR-92a 0.3249034 fail
From 335 potential target miRNAs, 277 total miRNAs were expressed over all
samples, and 72 miRNAs were expressed in all 20 samples. These 72 miRNAs
were candidate endogenous controls, following a series of statistical analyses
only five genes (miR-146a, miR-16, miR-195, miR-30e, and miR-744) passed the
criteria of ANOVA p.0.3, SD,1, and pair-wise |DDCT|,0.5.
doi:10.1371/journal.pone.0031278.t001
Figure 2. Five serum miRNAs as endogenous references stably expressed across different mouse strains. 2DCT values of miR-146a,
miR-16, miR-195, miR-30e, and miR-744 show stability across all samples (w=weeks). The 2DCT average of all five miRNAs is also displayed. Each
gene is expressed across all samples, has an ANOVA p.0.3, an SD,1 and all pair-wise |DDCT|,0.5.
doi:10.1371/journal.pone.0031278.g002
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accepted serum miRNA references.
Currently, there are no reliable human serum internal
references reported. It is unclear whether the identified five
miRNAs here are also stably expressed in human serum samples.
Notably, these five miRNAs, miR-16, miR-744, miR-195, miR-
146a, and miR-30e share a 100% identity between human and
mouse [32,33,34,35]. Interestingly, two recently published papers
reporting on serum miRNA biomarkers for specific diseases have
used miR-16 as an internal control to normalize qRT-PCR data
[16,36]. However, a large number of human samples are needed
to further validate this endogenous reference.
In conclusion, using a TaqManH real-time PCR miRNA array
and global gene expression normalization strategy, we have
analyzed 20 individual serum miRNA expression profiles from
multiple animal strains across different ages as well as different
conditions. We have found five miRNAs, miR-146a, miR-16,
miR-195, miR-30e, and miR-744 to be stably expressed in all
tested strains across different ages and conditions. Thus, these
miRNAs may be used as mouse serum miRNA endogenous
references necessary for single assay studies. The discovery of
consistent expression of these specific serum miRNAs will promote
the generation of more accurate miRNA expression profiles and
more accurate interpretation of qRT-PCR data. Although we are
convinced that these five miRNAs are the best circulating
endogenous references reported so far, the question why these
miRNAs are stable in mouse serum remains to be answered.
Further investigation into the function of these specific serum
miRNAs, the validation of their expression stability in different
disease conditions, and their expression stability in human samples
are needed.
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